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Abstract 
Inducible costimulator (ICOS) ligation in concert with TcR stimulation results in strong 
phosphoinositide 3-kinase (PI3K) activation in T lymphocytes. The ICOS cytoplasmic tail 
contains an YMFM motif that binds the p85α subunit of class IA PI3K, similar to the YMNM 
motif of CD28, suggesting a redundant function of the two receptors in PI3K signaling. 
However, ICOS costimulation shows greater PI3K activity than CD28 in T cells. We show in 
this report that ICOS expression in activated T cells triggers the participation of p50α, one of 
the regulatory subunits of class IA PI3Ks. Using different T-APC cell conjugate systems, we 
report that p50α accumulates at the immunological synapse in activated but not in resting T 
cells. Our results demonstrate that ICOS membrane expression is involved in this process and 
that p50α plasma membrane accumulation requires a functional YMFM SH2-binding motif in 
ICOS. We also show that ICOS triggering with its ligand, ICOSL, induces the recruitment of 
p50α at the synapse of T cell/APC conjugates. In association with the p110 catalytic subunit, 
p50α is known to carry a stronger lipid kinase activity compared to p85α. Accordingly, we 
observed that ICOS engagement results in a stronger activation of PI3K. Together, these 
findings provide evidence that p50α is likely a determining factor in ICOS mediated PI3K 
activity in T cells. These results also suggest that a differential recruitment and activity of 
class IA PI3K subunits represents a novel mechanism in the control of PI3K signaling by 
costimulatory molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
T lymphocyte activation is based on multiple and complex interactions between T 
cells and antigen presenting cells (APC). It is now commonly accepted that optimal T cell 
activation requires several independent signals (1). The first one, which determines the 
specificity of the immune response, is delivered through the antigen receptor interaction with 
the MHC-antigen complex on the APC surface. An additional costimulatory signal is crucial 
for complete T cell activation which leads to cytokine production and cell proliferation. On T 
cells, the best characterized costimulatory molecule is CD28, but several other costimulatory 
molecules like the ICOS inducible costimulator have also been described (2, 3). CD28 and 
ICOS (also known as CD278) deliver positive signals during T cell activation. They bind 
respectively to B7 molecules (B7.1/CD80 and B7.2/CD86) and ICOS ligand (ICOSL/CD275) 
expressed in various tissues, including APCs (4, 5). These two costimulatory receptors have 
unique and overlapping functions that synergize to regulate CD4+ T cell differentiation (6). 
CD28 is expressed in resting and activated T cells, while ICOS expression is induced upon T 
cell activation. ICOS binds to a specific ligand, ICOSL, that is expressed on both lymphoid 
and non-lymphoid cells (4, 5). Recent studies indicated that the ICOS-ICOSL pathway plays 
an important role in Th2 responses in asthma and allergies (7, 8), Th1-Th2 responses during 
bacterial infections (9, 10), tumor cell rejection and during the pathologic process of chronic 
graft rejection in vivo (11, 12). ICOS mediated costimulation leads predominantly to the 
production of effector cytokines such as IL-4 and IL-10  and to a lesser extend in the 
production of IL-2, IFN-γ and TNF-α (4, 13, 14).  
In humans, signaling pathways induced by the costimulatory molecule ICOS remain 
poorly understood. ICOS bears a unique YXXM signaling motif in its intracellular tail that 
binds the p85α regulatory subunit of phosphoinositide 3-kinase (PI3K) (7, 15). This is in 
contrast to CD28 that has several SH24 and SH3 binding motifs for proteins such as Grb2, 
GRID, Lck, Itk and Tec (16). ICOS signaling has been shown to essentially involve the PI3K 
pathway since so far, p85α is the only identified signaling molecule that interacts with ICOS 
(17). Although ICOS seems to be more limited in generating intracellular signals, ICOS 
stimulation in combination with TcR shows a much stronger capability to activate PI3K than 
CD28 (18, 19). Class IA PI3K is composed of a p110 catalytic subunit (either the α, β or δ 
isoforms) and a regulatory subunit which can be p85α, p55α or p50α (encoded by the 
pik3r1gene), p85β (encoded by the pik3r2 gene) or p55γ (encoded by the pik3r3 gene) (20). 
p85α, p55α and p50α regulatory subunits share a common C-terminal region consisting of 
two SH2 domains flanking the p110 catalytic binding site and have a unique N-terminal 
region of 304, 34 and 6 amino acids respectively (21).  
Although it has been showed that p50α associated PI3K activity in response to insulin 
stimulation is greater than p85α or p55α (21-23), little is known about their relative function 
and contribution during T cell activation. We therefore made the hypothesis that the 
difference in PI3K activity between ICOS and CD28 costimulation could be linked to a 
differential recruitment of the regulatory isoforms.  
In this study, we show that the p50α PI3K regulatory subunit is recruited by 
costimulatory receptors only on activated T cells. Despite similar expression levels before and 
after cell activation, we also report that p50α accumulates at the immunological synapse (IS) 
in activated but not in resting T cells. We show that ICOS may have a specific role in 
recruiting p50α at the membrane, as ICOS triggering induces p50α localization to the plasma 
membrane through its YMFM intracellular motif. Upon ICOS ligation, p50α associated PI3K 
activity is stronger than that associated with p85α. Finally ICOS but not CD28 ligation, 
induces a strong phosphorylation of Akt in activated T cells. Collectively, our results suggest 
that ICOS makes use of the p50α regulatory subunit to sustain PI3K activity in activated T 
cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 
Cells 
Human CD4+ T cells and monocytes were isolated from healthy blood donors by Ficoll 
density gradient centrifugation followed by negative and positive depletion respectively on 
magnetic beads (CD4+ T Cell Isolation Kit II human, CD14 microbeads, Miltenyi). To induce 
ICOS expression, CD4+ T cells were activated with CD3-CD28 coated beads (Dynabeads® 
CD3/CD28, Invitrogen) according to manufacturer’s instructions. Beads were removed after 
24 hrs of stimulation and cells were harvested for an additional 24 hrs. Peripheral blood 
monocytes were derived into dendritic cells (monocyte-derived DCs) in RPMI 10% FCS, 20 
ng/ml IL-4, 100 ng/ml GM-CSF (Abcys) for 5 days before a 24 hrs maturation period in the 
presence of 2.5 µg/ml of LPS (Sigma-Aldrich). The Jurkat cell line JA16 and the JICOS.1 
clone stably expressing the ICOS receptor were cultured in RPMI 10% FCS. To make the 
JICOS.1 cell line, human ICOS cDNA was cloned into a βDNA4 vector (24) between the 
NotI-SpeI restriction sites. The Raji B cell line was cultured in RPMI 10% FCS. L cells stably 
expressing the ICOS-L protein (L-LICOS cells) (25) or the B7.1 protein (L-B7.1 cells) (26) 
were cultured in DMEM 10% FCS. L-LICOS cells are a kind gift from R.A. Kroczek and 
H.W. Mages (RKI, Berlin, Germany).  
 
ICOS, CTLA-4 and PD-1 Fc fusion proteins 
Extracellular domains of ICOS, CTLA-4 or PD1 were amplified by PCR from human 
activated T cell cDNAs, and cloned in frame with the Fc fragment of the human IgG1 
sequence using the Cos Fc link vector (SmithKline Beecham Pharmaceuticals, King of 
Prussia, PA).  Fc fusion proteins were produced in COS cells harvested in CHO-S-SFM II 
medium (Invitrogen). Culture supernatants were collected 7 days after transfection, filtered 
and loaded on a 5-ml Affigel protein A column according to the manufacturer’s protocol 
(Bio-Rad). After washing, the proteins were eluted with a 0.1mol/L citrate buffer, pH 3.5, 
concentrated, and dialyzed against phosphate-buffer saline (PBS). Purification steps were 
monitored by ELISA using a sandwich revelation system with coated antibody anti-human 
IgG-UNLB and humain IgG-AP (Southern Biotechnology Associates) and revealed by pNPP 
substrate (Sigma). Purity and quality of the human Ig fusion proteins were controlled by gel 
electrophoresis and by cell surface staining on L-LICOS cells, L-B7.1 cells or PD-L1 
transfected COS cells.  
 
T cell stimulation/Immunoprecipitation/Immunoblotting 
Prior to immunoprecipitation or in order to measure the phosphorylation status of Akt, cells 
were stimulated with anti-CD3 antibody (clone 289) and anti-CD28 (clone CD28.2 [(27)]) or 
anti-ICOS antibody (# C398.4A, BioLegends) (10 µg/ml each), or with L-LICOS, L-B7.1 or 
L-LTK- cells for 15 min at a 1:2.5 ratio. Following stimulation, 1% NP40 cell lysates were 
subjected to immunoprecipitation with 5 µg of CD28.2 or ICOS antibodies and blotted with a 
polyclonal rabbit antiserum that recognizes all regulatory alpha subunits (anti-pan p85α, # 
06.195, Millipore). GFP-p50α and GFP-p85α constructs were transfected in Jurkat cells. Cell 
lyastes were immunoprecipitated with anti-GFP antibodies (clones 7.1 and 13.1, Roche 
Diagnostic) and immunoblot analyses were performed with rabbit GFP polyclonal antibody 
(#ab6556, Abcam) and Myc Tag antibody (# ab9106, Abcam). In order to disrupt receptor-
ligand interactions, L cells were pre-incubated with 10 µg/ml anti-LICOS (# 136726, R&D 
Systems) or anti-CD80 (clone 2D10.4, (26)) antibodies prior to stimulation. Cells were lysed 
and subjected to Western blot analyses with anti-phospho Akt, anti-Akt, anti-phospho-GSK-
3α/β (Ser21/9) and GSK-3α antibodies (#4060, #9272, #9331, #9338 respectively, Cell 
Signaling Technology).  
 
Constructs  
ICOS constructs consist of a Myc Tag epitope inserted between the signal peptide and the 
extracellular part of murine CD28 followed by the transmembrane and intracellular tail of 
human ICOS (see diagram Fig. 3B). In the ICOS Y180F construct, the tyrosine residue at the 
position 180 was mutated ton phenylalanine. Both constructs were cloned into a βDNA4 
vector. The GFP-p85α and GFP-p50α constructs were cloned according to the same 
procedures (28). Briefly, human p85α and p50α were cloned into pCR2.1-TOPO (Invitrogen 
Life Technologies) and then subcloned into the pEGFP-C1 fusion vector (BD Clontech) as an 
EcoRI restriction enzyme fragment, resulting in expression of a N-terminal GFP fusion 
protein. The Myc-p110δ construct is a kind gift from B. Vanhaesebroeck (Institute of Cancer, 
London, UK) and has been cloned according to previously published data (29). 
 
Cell transfections 
Freshly prepared human unstimulated (U-023 program) or CD3+CD28 stimulated (U-024 
program) primary CD4+ T cells were transfected with the Nucleofector technology (AMAXA 
biosystems) according to the manufacturer’s instructions with 5 µg of the indicated construct.  
Jurkat cell lines were transfected using the Biorad apparatus Gene Pulser Xcell (250V, 25ms, 
4mm) with 20 µg of the indicated construct for 24 hrs. 
 
Determination of PI3K activity 
107 activated CD4+ T cells (transfected or not with GFP constructs) were left unstimulated or 
were stimulated for 15 min at 37 °C with L-LICOS or L-B7.1 cells at a 1:2.5 ratio. The cells 
were lysed for 10 min with 0.5 ml of 1% NP-40 lysis buffer. ICOS, CD28 or GFP 
immunoprecipitates were performed from whole-cell lysates for 2 hrs at 4 °C, and washed 
with TNE buffer (10 mM Tris–HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA and 0.1 mM 
sodium orthovanadate). The PI3K activity was determined using a PI3-kinase ELISA kit 
according to manufacturer’s instructions (Echelon Biosciences, Salt Lake City, UT, USA). 
For each condition, the kinase reaction was run in triplicates. 
 
Immunofluorescence labelling 
ICOS Capping. Capping experiments were performed according to previously published 
procedures (30). Briefly, 107 T cells were incubated with anti-Myc antibody (Santa Cruz) at 
4°C for 30 min followed by an additional 30 min incubation with Alexa 594 goat anti-mouse 
antibody (Sigma). Capping was performed at 37°C for 15 min. Cold PBS was added to stop 
the reaction, and cells were fixed and analyzed by confocal microscopy. Jurkat/Raji 
conjugates. To distinguish APCs from Jurkat cells, Raji B cells were loaded with Cell 
Tracker® Red CMTMR (Molecular Probes) for 30 min at 37°C, washed, and resuspended in 
RPMI 1640 with 10% FCS. Cells were then incubated for 15 min in the presence of 1 µg/ml 
of SEE Superantigen (Toxin Technology). Jurkat cells were mixed with an equal number of 
Raji cells in a final volume of 100 µl and were incubated at 37°C for 20 min. Conjugates were 
plated on poly-L-lysine-coated coverslips and fixed for 20 min in 4% formaldehyde. T cells/L 
cells conjugates. To distinguish APCs from T cells, L-LICOS or L-B7.1 cells were plated on 
poly-L-lysine-coated coverslips one day before and then loaded with Cell Tracker® Red 
CMTMR (Molecular Probes) for 30 min at 37°C, washed, and resuspended in RPMI 1640 
with 10% FCS. T cells were added at a ratio of 1:3 for 20 min and fixed as above. T 
cells/moDC conjugates. DCs were plated, loaded with the cell tracker and pulsed with a 
cocktail of superantigens (SEA, SEB, SEC, SEE [final concentration, 1 ng/µl each], Toxin 
Technology) at the same time for 1 hr at 37°C. Before conjugation, receptor-ligand blockade 
was performed using Ig constant fragment fusion proteins at 10 µg/ml each for 1 hr on DC’s. 
T cells were then added at a ratio of 1:3 for 20-45 min. Cells were fixed as described above. 
The proportion of conjugates with GFP-p50α or GFP-p85α redistributed to the cell/cell 
contacts was calculated by randomly choosing 300 different conjugates. For p50α/ICOS 
colocalization experiments, GFP-p50α transfected T cells were mixed with DCs as previously 
described. T cells were labelled with indirect fluorescence staining using anti-ICOS antibody 
(# C398.4A, BioLegends) for 1 hr followed by Alexa Fluor 546 goat anti–hamster antibody 
(Molecular Probes) staining for 30 min. Confocal microscopy was carried out on a Zeiss LMS 
510 META using a 63 x 1.4 oil Plan-Apochomat objective lens. For cytometry analysis, cells 
were labelled with CD28-PE and ICOS-PE antibodies (clones # CD28.2 and DX29 
respectively, BD Biosciences Pharmingen).  
 
Statistical analysis  
Statistical analysis was performed with the Wilcoxon-Mann-Whitney test using Cytel's 
StatXact® software. Values of p < 0.05 were considered significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
The p50α PI3K regulatory subunit is recruited by costimulatory receptors only on activated T 
cells.  
 
Class IA PI3K members have been implicated in immune T cell signaling. However, little is 
known about the expression status of PI3K regulatory subunit isoforms in hematopoietic cell 
lines and in particular, in human T lymphocytes. Indeed, most studies involving PI3K 
signaling events focussed on p85α expression and function neglecting the participation of 
other PI3K regulatory subunits. In order to determine the expression pattern of class IA PI3K 
regulatory subunits in resting and activated human T cells, Western blot analyses of cell 
lysates with a polyclonal antiserum that recognizes all regulatory alpha subunits were 
performed (Fig. 1A). In resting T cells, two bands corresponding to p85α and p50α were 
detected. An additional 55kDa band corresponding to p55α, appeared in activated T cells. 
Like the CD28 costimulatory receptor, ICOS, whose expression is induced following T cell 
activation (Fig. 1B), is known to bind the p85α regulatory subunit. Upon CD28 or ICOS 
ligation, the binding of the different PI3K regulatory subunits to CD28 or ICOS was next 
investigated. As shown in Fig. 1C, (left panel), in resting T cells, p85α but not p50α is able to 
interact with CD28 following receptor triggering. In activated T cells, a slight constitutive 
association of p85α and p55α with ICOS and CD28 was observed. However, ICOS triggering 
(alone or in combination with CD3 antibody) led to the recruitment of p50α within the 
receptor. ICOS ligation also greatly enhanced its association with p85α compared to 
unstimulated or CD3+CD28 stimulated T cells (Fig. 1C, middle panel). Thus, similar levels of 
p85α and p50α association to CD28 or ICOS were detected upon stimulation, but 
surprisingly, ICOS ligation promoted CD28 association “in trans” with the two regulatory 
subunit isoforms as efficiently as CD28 triggering (Fig. 1C, right panel). These results 
demonstrate a selective recruitment of p50α to ICOS and CD28 receptors in activated T cells. 
They also suggest that ICOS triggering strengthens CD28 interactions with class IA alpha 
regulatory subunits.  
ICOS costimulation shows a stronger ability to activate PI3K than CD28 costimulation 
(19). Using PI3K activity ELISA kit, we showed that ICOS ligation induces a higher PI3K 
activity in activated T cells compared to CD28 ligation (Fig. 1D). As it has been previously 
reported that p50α and p85α are carrying distinct PI3K activities (21-23), these observations 
prompt us to investigate the dynamic of recruitment of these regulatory subunits at the plasma 
membrane of activated T cells. 
 
The p50α regulatory subunit localizes at the immunological synapse on activated T 
lymphocytes. 
 
The p85α and p50α regulatory subunits are derived by alternative splicing of the same gene 
pik3r1 (31). These molecules share two SH2 domains, the p110-binding inter-SH2 domain 
and a proline-rich region. They differ in their N-terminal domain: p50α has a unique 6 amino-
acid sequence and p85α has a specific Bcr homology domain (BH) and a SH3 domain. We 
used GFP fusion proteins of p85α and p50α (Fig. 2A) in order to visualize the recruitment of 
these regulatory subunits in T cell/APC conjugates. It is now commonly accepted that class 
IA PI3K regulatory subunits stabilize the unstable and labile p110 catalytic subunits (32). To 
verify that our GFP-p50α and GFP-p85α constructs were functional, immunoprecipitation 
experiments were carried out in Jurkat T cells coexpressing a Myc-tagged form of the p110δ 
catalytic subunit and either GFP-p50α or GFP-p85α. Unlike the GFP molecule used in the 
control, both GFP-p50α and GFP-p85α constructs bind the co-transfected p110δ catalytic 
subunit molecule (Fig. 2B). We next evaluated p85α and p50α recruitment to the 
immunological synapse in a system of T-DC conjugates by mixing SAg pulsed DCs with 
either resting T cells or activated T cells transfected with GFP-p50α or GFP-p85α constructs 
(Fig. 2C). A similar GFP-p50α or GFP-p85α relocalization to the immunological synapse was 
observed at different times of cell conjugates formation (data not shown). Imaging analysis of 
the formed conjugates showed that p50α and p85α regulatory subunits were differentially 
recruited to the T-DC contact area depending on the activation state of T cells (Fig. 2D). 
Thus, p50α was recruited exclusively at the IS in activated T cells, whereas p85α was 
similarly recruited at the IS in resting or activated T cells.  
 
ICOS overexpression brings p50α to the immunological synapse through its YxxM motif. 
 
As shown previously, the p50α regulatory subunit preferentially localizes at the contact zone 
between an activated T lymphocyte and a dendritic cell (Fig. 2D), and the ICOS receptor 
seems to be a good candidate for recruiting the adaptor protein when triggered by its ligand 
(Fig. 1C). To further demonstrate the role of ICOS in recruiting p50α at the IS, we analyzed 
its localization in conjugates formed between Jurkat cells stably expressing ICOS (JICOS.1) 
or Jurkat parental cells (JA16) and SEE-pulsed Raji B cells, an APC known to express ICOS 
ligand (40). As shown in Fig. 3A, upper panel, the two cell lines only differ in ICOS 
expression levels. While JICOS.1 cells express high level of ICOS, JA16 cells express very 
low levels of the ICOS costimulatory receptor. Both T cell lines express the CD28 receptor at 
a similar level. p50α was found to be recruited to the IS twice as much in JICOS.1/Raji cell 
conjugates in comparison to JA16/Raji cell conjugates, showing that the increase in ICOS 
expression led to greater p50α accumulation to the immunological synapse. In contrast, p85α 
was recruited similarly by both T cell lines (Fig. 3A). We next investigate the role of the 
ICOS YxxM intracellular motif in this process, a motif which has previously been shown to 
recruit p85α (7). Tyrosine residue 180 in the YMFM motif was mutated to phenylalanine in a 
Myc-tagged chimeric molecule composed of the extracellular domain of murine CD28 fused 
to the cytoplasmic domain of human ICOS (Fig. 3B, upper panel). Localization of this ICOS 
mutant together with GFP-p50α or GFP-p85α molecules was analyzed after anti-Myc-
mediated capping. As shown in Fig. 3B, lower panel, the GFP-p50α molecule is distributed 
throughout the cell before capping. Upon Myc cross-linking, GFP-p50α was substantially 
recruited at the plasma membrane and identically localized with the ICOS receptor into caps. 
Tyrosine mutation into phenylalanine abrogated ICOS and GFP-p50α colocalization at the 
membrane surface. While ICOS aggregated into caps, GFP-p50α remained diffused in the 
whole cell. Taken together, these data provide evidence that ICOS expression drives p50α 
relocalization at the IS via its YxxM motif. 
 
ICOS and p50α localize at the immunological synapse in activated T cells. 
 
We showed that ICOS ligation induced p50α association within the intracellular tail of the 
receptor (Fig. 1C), and that ICOS overexpression in Jurkat cells led to increased p50α 
localization at the IS (Fig. 3A). As ICOS may have a specific role in recruiting the p50α 
regulatory subunit to the plasma membrane in activated T cells, we directly investigated ICOS 
and GFP-p50α localization to the IS between activated CD4+ T cells and dendritic cells. Fig. 
4A shows that ICOS and p50α colocalized at the contact zone. To further analyse the 
contribution of ICOS in this recruitment of p50α, we used Fc-fusion proteins containing the 
extracellular domain of ICOS or CTLA-4 to disrupt specific interactions between the 
receptors and their respective ligands (Fig. 4B). A PD-1-Fc fusion molecule was used as a 
control. By disturbing the ICOS/ICOS-L interaction with an ICOS fusion protein, a slight 
decrease in p50α recruitment at the IS was observed in activated T cells. In contrast, CTLA-
4-Fc disruption of CD28/CD80 interactions affected predominantly p85α IS localization. We 
also performed cell conjugates between L-LICOS or L-B7.1 cells and activated T cells which 
allowed the triggering of ICOS or CD28 with a limited contribution of other molecules 
expressed on T cells. The results showed that p85α was similarly recruited at the contact area 
when ICOS or CD28 was engaged by its respective ligand. In contrast, ICOS-L was much 
more efficient than B7.1 in triggering p50α localization at the cell-cell contact (Fig. 4C). In 
order to selectively determine the PI3K activity associated to the different regulatory isoforms 
under ICOS ligation, activated T cells were transfected with GFP, GFP-p50α or GFP-p85α 
constructs for 24 hrs. Similar level of GFP proteins were detected by flow cytometry (data not 
shown). T cells were then stimulated with L-LICOS cells for 15 min as previously described. 
The PI3K assay was performed on GFP immunoprecipitates (Fig. 4D). Surprisingly, the GFP 
protein alone, used as a control, showed a basal PI3K activity. Nevertheless, the PI3K activity 
associated with both regulatory subunit isoforms (GFP-p50α or GFP-p85α) was higher 
compared to our control (GFP alone). As previously described for the insulin receptor system 
in muscle homogenates (21), p50α associated PI3K activity was higher compared to p85α 
upon ICOS ligation in activated T cells. Together, these data provide strong evidence that 
ICOS receptor expression and engagement facilitate p50α localization at the plasma 
membrane in activated T cells, thus probably leading to the strong PI3K activity associated to 
the receptor. 
 
ICOS ligation alone, but not CD28, is able to induce a strong phosphorylation of the PI3K 
effector Akt.  
 
Although little is known about ICOS signaling pathways, it is now clearly established that 
ICOS is a major PI3K activator associated with strong kinase activity (7, 19), thus leading to 
strong subsequent phosphorylation of PI3K downstream effectors such as PDK1 and Akt/ 
PKB (18, 33). To investigate the role of ICOS mediated PI3K activity in T cell conjugates, we 
performed ICOS triggering with ICOS ligand overexpressing L cells and analyzed the 
phosphorylation status of the serine/threonine kinase Akt/PKB (Fig. 5). Briefly, activated T 
cells remained unstimulated or stimulated either with a combination of CD3+CD28 antibodies 
or with L-LICOS or L-B7.1 cells. In order to determine the activation status of Akt, a kinetic 
analysis of its phosphorylation was performed on activated T cells. As shown in Fig. 5A, 
ICOS ligation by its natural ligand induced a stronger Akt phopshorylation than CD28, at any 
tested time of stimulation from 5 to 60 min, reaching its maximum after 15 min. The same 
experiments were performed with blocking mAbs to analyse the specific contribution of ICOS 
in this event. In order to disrupt ICOS/ICOS-L or CD28/B7.1 interactions, L-cells were 
previously incubated for 15 min with anti-ICOS-L or anti-CD80 antibodies and used to 
stimulate activated T cells. Fig.5B showed that this very strong Akt phosphorylation induced 
by ICOS was specific as it was blocked after anti-ICOS-L pre-incubation. Following its 
activation, Akt phosphorylates the glycogen synthase kinase-3 (GSK-3), thus leading to its 
inactivation (34). A significant basal GSK-3 phosphorylation was detected in activated T cells 
that could reflect the activated status of these cells. However, amongst the different stimuli 
used to further activate the cells, ICOS ligation induced the strongest increase in GSK-3 
phosphorylation which was partially blocked by the anti-ICOS-L antibody (Fig. 5B). Taken 
together, these data show that ICOS ligation leads to a strong activation of PI3K/Akt-
dependent signaling pathways in activated T cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion  
 
In T cells, Class IA PI3Ks are typically activated downstream of TcR and 
costimulatory molecule engagement. Mice lacking the major class IA regulatory subunits 
show selective impairments in T cell function and critical defects in costimulatory mediated 
events (35). In particular, pik3r1 and pik3r2 defective T cells have reduced helper functions 
for B cells. Due to genetic and functional redundancy of regulatory and catalytic PI3K 
subunits, and because of compensatory effects between all the class IA PI3K members, 
discrimination of individual regulatory subunit associated functions remains difficult to 
investigate (36-38). Previous studies investigating PI3K signaling events and functions mostly 
focussed on p85α participation. However, there is now growing evidence that differences in 
the use of regulatory and/or catalytic subunits might occur through costimulatory receptors or 
adaptor proteins and that PI3K members probably display distinct biological and signaling 
functions (36).  
ICOS and CD28, both members of the CD28 family of costimulatory receptors, recruit 
the p85α regulatory subunit, thus leading to PI3K activation and signaling (7, 26). Expressed 
following T cell activation, ICOS shows much stronger PI3K activity compared to CD28 (Fig. 
1D), as it is able to produce greatest amounts of PtdInsP3 leading to strong subsequent 
phosphorylation of the serine/threonine kinase Akt/PKB, a key PI3K effector (18, 19). The 
mechanism of PI3K regulation has been well described in insulin signaling (39). All studies 
performed on the PI3K signaling pathway associated with the IRS-1 protein tend to show the 
same results and confer to the p50α-p110 complex a stronger PI3K activity compared to p55α 
or p85α regulatory subunits (21). We postulated that ICOS could be a good candidate in 
differentially recruiting PI3K regulatory subunits within its intracellular YxxM binding motif 
and that the p50α regulatory subunit could play an important role in ICOS mediated PI3K 
activity. Indeed, ICOS associated PI3K signaling pathway seems to be the “key” pathway 
involved in receptor functions. Consistent with previous studies (17), pulldown experiments 
performed with phospho-YxxM peptides, followed by mass spectrometry analysis showed 
that a unique PI3K signaling pathway is involved in ICOS mediated costimulation. The ICOS 
intracellular tail exclusively allows functional binding of the regulatory subunit isoforms of 
class IA PI3K who can in turn, recruit the p110 catalytic subunits (Camille Fos, Stéphane 
Audebert, data not shown). We also corroborate data showing that the same YxxM 
intracellular motif of CD28 is a scaffold for several signaling pathways, as it is able to recruit 
proteins such as Sos1/2, Cbl, SLP-76, Grb2, and GRID (36). Unlike CD28 that is constituvely 
expressed, ICOS can only be detected on the surface of activated T cells (4) (Fig. 1B). Both 
p50α and p85α are expressed on resting T cells, but only p85α binds to CD28 upon receptor 
ligation (Fig. 1A and 1C). On activated T cells, ICOS triggering leads to p50α accumulation 
to the immunological synapse and association with the YMFM motif of the receptor (Fig. 3). 
In contrast to p85α and p55α that are associated with ICOS at a basal state, p50α association 
with the receptor is an inducible event that occurs following ICOS ligation (Fig. 1C). Basal 
association of p85α to the receptor is greatly increased upon ICOS ligation. This basal 
association of p85α and p55α is also found in CD28 immunoprecipitates and CD28 ligation 
significantly increases the association of regulatory subunits with the receptor. Surprisingly, 
ICOS ligation promotes and induces p50α association with CD28 in a way that remains to be 
explored. However, one can imagine that ICOS brings p50α to the immunological synapse, 
perhaps in membrane signaling microdomains, and thus provides a p50α reserve to other 
transmembrane receptors involved in T cell activation (40-42). In the same way that CD28 
has been shown to enhance and sustain TcR signaling, we can now consider that the ICOS 
receptor is able to cooperate with CD28 and to strengthen CD28 induced signaling pathways. 
A cross-talk between the two CD28 family members may occur at the immunological synapse 
and needs to be further investigated. 
By using different T/APC cell conjugates, we show that ICOS is efficient in bringing 
p50α to the immunological synapse. By using a T cell model overexpressing ICOS (Fig. 3A) 
or by triggering ICOS alone with limited contribution of other costimulatory molecules (Fig. 
4C), we show that ICOS plays a critical role in recruiting p50α to the plasma membrane. On 
T/DC cell conjugates, the participation of ICOS is more difficult to evaluate. When blocking 
ICOS/ICOS-L (or CD28/CD80) pathway, only a slight but significant decrease is observed in 
p50α or p85α relocalization to the immunological synapse (Fig. 4B). Indeed, in this 
physiological context, several PI3K adaptors and YxxM bearing receptors are involved in 
recruiting PI3K to the membrane and their relative contribution is difficult to evaluate. siRNA 
directed to p50α or p85α were designed in order to selectively extinguished these regulatory 
subunits and to investigate their role in ICOS mediated PI3K signaling and effector functions. 
Unfortunately, we were not able to downregulate PI3K gene expression in human T cells or in 
other T cell lines. p85α and p50α expression remained the same in all analysed conditions. 
Furthermore, when a downregulation was observed in heterologous cell lines, both regulatory 
subunits were touched in a non selective way (data not shown). Knock-out mice models of 
pik3r genes showed that class IA PI3K regulatory subunits are important for T cell functions 
(35, 38). Great efforts have been made to better understand the participation of each 
regulatory subunit but there is real difficulty in evaluating the relative contribution of each 
subunit because of compensatory effects between class IA members. Since we show that p50α 
accumulates to the IS in activated T cells only, the phenotype of pik3r knock-out mice should 
be reevaluated in secondary responses when receptors susceptible to associate with p50α are 
expressed. Indeed, maintenance of T cell longevity has been shown to involve OX40 
costimulation-regulated duration of Akt activation (43). Like OX40 that is induced following 
T cell activation, ICOS ligation provides a strong activation signal for the serine/threonine 
kinase Akt (Fig. 5), which can in turn regulate antiapoptotic molecules such as GSK-3. 
Following T cell activation, the PI3K/Akt/GSK-3 pathway might thus be involved in IL-10 
production by ICOS expressing cells. Indeed, previous data showed that Akt mediated GSK3 
inactivation promotes a great increase in IL-10 production following Toll-like receptor 
ligation (44). In contrast to CD28 that predominantly acts during the primary response, ICOS 
plays a role in restimulation and clonal expansion of T and B effector cells during secondary 
responses. ICOS, whose expression has been described not only on freshly activated T cells, 
but also on regulatory and memory T cells, can interact with its ligand on non-professional 
and non-hematopoietic “APCs” such as epithelial or endothelial cells under pro-inflammatory 
conditions (45, 46). ICOS ligation in inflamed peripheral tissues could thus induce a sustained 
PI3K activation thereby regulating T cell energy metabolism and allowing quick and efficient 
responses to antigen restimulation (47). Animal models targeting exclusively the p50α 
regulatory subunit would be useful for further evaluating p50α functions in metabolism and 
regulation of activated T cells. 
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Figure legends 
 
Figure 1. p50α regulatory subunit associates with YxxM bearing receptors in activated 
but not in resting T cells. A. Immunoblot analysis of class IA PI3K regulatory subunits 
expression in human CD4+ resting versus CD3+CD28 microbeads activated T cells for 48 
hrs. Data represent 3 different donors. B. Flow cytometry analysis of resting or activated T 
cells stained with phycoerythrine (PE) labelled anti-CD28 or anti-ICOS antibodies. C. 
Binding of class IA regulatory subunits to YxxM costimulatory receptors. Resting or activated 
CD4+ T cells were stimulated for 15 min with anti-CD3 plus anti-CD28, anti-CD3 plus anti-
ICOS antibodies or LICOS or B7.1 expressing cells. Cell lysates were subjected to CD28 or 
ICOS immunoprecipitation and a class IA regulatory subunit (pan p85) Western blot was 
performed. Data are representative of 2 independent experiments. Molecular weight standards 
(kDa) are indicated on the left side of the panel. D. ICOS and CD28 associated PI3-kinase 
activity. Following receptor ligation, cells were lysed and receptors immunoprecipitations 
were performed. The PI3-kinase activity was quantified in immunoprecipitates with an 
ELISA plate reader. Results are expressed in pmoles of produced PIP3 per 106 T cells. Bars 
indicate means ± SEM of triplicate determinations.  
 
Figure 2. The p50α regulatory subunit accumulates at the immunological synapse in 
activated but not in resting T cells. A. Schematic representation of GFP-PI3K regulatory 
subunit constructs and their interaction with p110 catalytic subunit. B. Jurkat T cells were co-
transfected with the p110δ-myc and GFP-p50α or GFP-p85α constructs for 24hrs. 
Immunoprecipitation with anti-GFP antibodies was performed followed by a anti-GFP or anti-
Myc antibody Western blot. C. Differential interference contrast (DIC) and green 
fluorescence images of GFP-p50α or GFP-p85α relocalization between transfected T cells 
and DC conjugates. Resting or activated human CD4+ T cells transfected with GFP-p50α or 
GFP-p85α constructs were mixed with mature dendritic cells for 20 min at a ratio of 1:3. DCs 
were previously pulsed with a cocktail of SAg. D. The proportion of conjugates with GFP-
p50α or GFP-p85α redistributed to the cell/cell contact was calculated by randomly choosing 
300 different conjugates for each experiment. Results shown in diagrams correspond to 3 
experiments ± SD values. Asterisks indicate significant p-values (p < 0.05). 
 
Figure 3. Upregulation of ICOS expression allows p85α and p50α association through its 
YxxM motif. A. Upper panel. Flow cytometry analysis of Jurkat cells (JA16) or ICOS 
overexpressing Jurkat cells (JICOS.1) using PE labelled anti-ICOS antibody or PE labelled 
anti-CD28 antibody. Lower and right panels. p50α and p85α relocalization at the IS between 
JA16 or JICOS.1 and SEE pulsed Raji B cells. JA16 or JICOS.1 cells transfected with GFP-
p50α or GFP-p85α constructs were mixed with Raji B cells for 20 min at a ratio of 1:1. Raji 
B cells were previously labelled with cell tracker CMTMR. The proportion of conjugates with 
GFP-p50α or GFP-p85α redistributed to the cell/cell contact was calculated by randomly 
choosing 300 different conjugates for each experiment. Results shown in diagrams correspond 
to 3 experiments ± SD values. Asterisks indicate significant p-values (p < 0.05). B. Capping 
experiments were performed on human activated T cells co-expressing MycICOS wt or 
MycICOS Y180F and GFP-p50α or GFP-p85α constructs. Briefly, the cells were incubated 
with anti-Myc antibody on ice for 30 min and then with goat anti-mouse Alexa 594 antibody 
for an additional 30 min. The capping of ICOS was performed at 37°C for 15 min. Cells were 
fixed on paraformaldehyde and analyzed by confocal microscopy.  
 
Figure 4. ICOS accumulates at the immunological synapse in T/DC conjugates and 
colocalizes with p50α PI3K regulatory subunit. A. Activated T cells were transfected with 
the GFP-p50α construct and mixed with mature dendritic cells at a ratio of 1:3. DCs were 
previously pulsed with a cocktail of SAg. ICOS localization at the immunological synapse 
was investigated by cell labeling of T/DC conjugates with an anti-ICOS antibody followed by 
goat anti-hamster Alexa 546 antibody. B. Activated human T cells transfected with GFP-p50α 
or GFP-p85α construct were mixed with mature DC for 20 min at a ratio of 1:3 (B) or with L-
LICOS or LB7.1 cells (C). The proportion of conjugates with GFP-p50α or GFP-p85α 
redistributed to the cell/cell contact was calculated by randomly choosing 300 different 
conjugates for each experiment. Results shown in diagrams are corresponding to 3 
experiments ± SD values. Asterisks indicate significant p-values (p < 0.05). In the panel B, 
the Y axis corresponds to the relative percentage of GFP constructs relocalization at the IS in 
presence of blocking reagents. The percentage obtained in cell conjugates formed without 
blocking fusion proteins was considered as 100%. D. GFP-p50α and GFP-p85α associated 
PI3-kinase activity. Activated T cells were transfected with a GFP, a GFP-p50α or a GFP-
p85α construct as previously described. Following ICOS ligation, cells were lysed and a GFP 
immunoprecipitation was performed. The PI3-kinase activity was quantified in 
immunoprecipitates with an ELISA plate reader. Results are expressed in pmoles of produced 
PIP3 per 106 T cells. Bars indicate means ± SEM of triplicate determinations.  
 
Figure 5. ICOS ligation induces a strong activation of PI3K signaling dependent events. 
A. Time course analysis of Akt phosphorylation upon ICOS or CD28 ligation. Human 
activated CD4+ T cells were left unstimulated (NS) or stimulated for 5 min with anti-CD3 
plus CD28 antibodies, ICOS ligand expressing L cells (L-LICOS) or B7.1 ligand expressing 
L cells (L-B7.1) for indicated times. B. In order to disrupt receptor-ligand interactions, 
activated T cells were stimulated as above for 15 min with L-LICOS or L-B7.1 cells pre-
treated with anti-ICOS-L antibody (B7-H2 Ab) or anti-CD80 antibody (2D10). L-cells were 
used as a negative control. Cell lysates were loaded to a 10% SDS-PAGE and Western blot 
analyses were performed with phospho-Akt (Ser473) or Akt specific antibodies and then 
reprobed with phospho-GSK-3α/β (Ser21/9) and GSK-3α antibodies. The relative positions of 
α and β GSK-3 are indicated by arrows. Data are representative of 3 independent 
experiments. 
 
 
 





